Radiotherapy for Orbital Metastases

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Radiotherapy for Orbital Metastases

The incidence of primary tumors that metastatisize to the orbit is approximately 7%. The most common malignant primary tumors in adults metastasizing to the orbital are breast cancer (42%), lung (11%), unknown primary (11%), prostate (8.3%), melanoma (5.2%), gastro-intestinal tract (4.4%) and kidney cancer (3.2%). Orbital metastases spread hematogenously, as there are no significant lymphatics in the orbit. The median survival after diagnosis of orbital metastasis has been reported to be approximately 9 months. In 19% of the cases, there is no history of cancer when the patient presents ophthalmic symptoms. Unilateral ptosis due to orbital metastases is rarely the first sign of lung cancer.

Citation: Resuli B, Lisi R, De Felice F, Musio D, Tombolini V (2014) Hypofractionated Stereotactic Radiotherapy for Orbital Metastases: A Case Report and Review of Literature. J Cytol Histol 5:273.


  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger